A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011.

Background: Of the 1.6 million South African people infected with human immunodeficiency virus (HIV), approximately 970,000 (55%) have been initiated on HAART. Despite these numbers, very little has been published about the safety profile of antiretroviral (ARV) medicines in the country.